This Phase Ib/II study evaluated the safety and efficacy of combining toripalimab with the gemcitabine plus nab-paclitaxel regimen as first-line treatment for locally advanced or metastatic PDAC and explored predictive biomarkers.
[Signal Transduction and Targeted Therapy]
